Less than two weeks after BioMarin Pharmaceutical Inc. opted to discontinue the entire development of the Prosensa portfolio, the company mentioned it would be abandoning another mid-stage asset for Pompe disease as it tries to be more prudent about spending.
BioMarin has said publicly that it hopes to break even or better in 2017, but that goal is going to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?